Plate Nº 86 · recorded October 3, 2026
Health & Medicine ResearchReported finding
Protective Enzyme UBE2N May Keep Fatty Liver Disease From Worsening
Scientists at Cedars-Sinai found the enzyme UBE2N declines as fatty liver disease worsens; restoring it in mice reduced fat, inflammation and scarring.
By James Calloway3 min read693 words
In brief
- An estimated 100 million Americans have MASLD, and 20–25% of them develop the more serious form, MASH.
- Researchers found that UBE2N enzyme levels decline in liver cells as the disease becomes more advanced.
- Restoring UBE2N in mice reduced fat accumulation, inflammation and scarring, suggesting a possible treatment target.
Scientists have identified an enzyme that may act as a natural defense against the worsening of fatty liver disease, a condition affecting an estimated 100 million Americans. The enzyme, called UBE2N, helps liver cells clear away damaged mitochondria and break down fat, potentially preventing the inflammation, scarring and cell damage linked to a more dangerous form of the disease.
The findings come from a preclinical study co-led by researchers at Cedars-Sinai Health Sciences University and published October 3, 2026, in the journal Nature Metabolism. While the work was done in cells and laboratory mice rather than in patients, it points toward a possible new strategy for preventing serious liver injury and the progression toward liver failure.
A common disease with few options
About 100 million people in the U.S. have metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, according to the American Liver Foundation. Roughly 20% to 25% of them go on to develop metabolic dysfunction-associated steatosis hepatitis, or MASH — a more serious form in which excess liver fat comes with inflammation, cell injury and scarring.
MASH is difficult to treat. Current care mainly centers on lifestyle changes and efforts to limit additional liver damage. Some medications are available, but treatment options remain limited, and there is currently no cure.
What the researchers found
Earlier research had suggested that damaged mitochondria — the tiny structures that produce energy for cells — may contribute to the development and progression of MASH. Building on that idea, the multicenter team measured UBE2N levels in liver cells as the disease advanced.
They found that levels of the enzyme decline as the disease becomes more severe.
"The UBE2N enzyme appears to protect the liver from the inflammation and damage associated with MASH by helping remove damaged mitochondria and supporting the breakdown of fat," said Ekihiro Seki, MD, PhD, professor of Medicine and Biomedical Sciences at Cedars-Sinai and co-corresponding author of the study. "When levels of the enzyme fell, we saw more damaged cells and injury to the liver."
In other words, UBE2N seems to work as a cellular cleanup crew. It helps dispose of broken mitochondria before they cause harm, and it supports the processing of fat that would otherwise accumulate in the liver.
Restoring the enzyme helped mice
The researchers then tested what happens when the enzyme is brought back. They restored UBE2N to normal levels in the livers of laboratory mice. After doing so, they observed reductions in three hallmarks of the disease: fat accumulation, inflammation and scarring.
Those results suggest that UBE2N could become a potential treatment target for stopping MASLD before it advances to MASH.
"The identification of this enzyme's role in regulating mitochondria in the liver is an important advance in understanding steatotic liver disease," said Shelly Lu, MD, the Women's Guild Chair in Gastroenterology and director of the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai. "Future studies can test whether enhancing this protective pathway can complement existing treatments, identify patients most likely to benefit and lead to new therapeutic approaches for preventing advanced disease."
Important caveats
The results are preliminary. The study was preclinical, meaning it involved experiments in cells and animals rather than human trials, so it is too early to say whether boosting UBE2N would help patients. Whether the same mechanism operates the same way in humans, and whether a drug can safely enhance it, remain open questions that future research will need to address.
Still, the discovery gives researchers a concrete molecular handle on a disease that affects tens of millions of people and lacks a cure. If follow-up studies confirm the findings, enhancing this protective pathway could eventually complement existing treatments or help identify patients most likely to benefit from early intervention.
The study's additional Cedars-Sinai authors include Michitaka Matsuda, So Yeon Kim, Takashi Tsuchiya and Yoon Seok Roh. The research was supported by funders including the National Institutes of Health, the National Research Foundation of Korea, the American Association for the Study of Liver Diseases, the San Diego Digestive Diseases Research Center, and the National Natural Science Foundation of China.
via cedars-sinai.org (Original)
More from James Calloway
Nearby plates
- Drug That Flips Cell 'Energy Saver' Switch Extends Animal Lifespans
- Microplastics Clog Liver Immune Cells and Drive Fat Buildup in Mice
- Triple-Action Drug Retatrutide Delivers Major Weight Loss in Type 2 Diabetes
- When 'Healthy Fats' Undermine Cancer Immunity: Yale Study
- Why a Food Poisoning Bacterium Can Also Cause Severe Wound Infections